AP-305™ Antibody Drug Conjugates

AP-305™ First in Class Antibody Drug Conjugates

Heat Shock Protein 70: a cancer biomarker protein discovered to be highly expressed on the cell membrane of many liquid and solid tumors, but not on healthy cells.

Tumors expressing membrane Hsp70 (mHsp70) release exosomes from tumors that, levels of which reflect tumor size and disease recurrence.

Most cancers express membrane Hsp70 (Gabriele Multhoff, unpublished data).

Metastases (the major cause of death by cancer) express even higher amounts of mHsp70 than primary tumors.
Antibody-Drug Conjugates (ADCs) are a form of targeted immunotherapy composed of a monoclonal antibody attached, via a linker, to a chemotherapy ‘warhead’. Unlike chemotherapy, ADCs can target and kill cancer cells while sparing healthy cells.

AP-305™: Novel Antibody Drug Conjugate (ADC) based on our proprietary cmHsp70.1 monoclonal antibody recognizing mHsp70 conjugated via a linker to a chemotherapy drug.

Antibody: The cmHsp70.1 monoclonal antibody selectively accumulates in tumors expressing mHsp70, but not in healthy cells.

Linker and Payload: Alphageneron is collaborating with a global biotechnology company for their clinical stage linker-drug conjugate

Patents: Granted and pending patents.

Stangl et al., J. Cell. Mol. Med. Vol 15, No 4, 2011 pp. 874-887